علاج السل الرئوي الحساس للأدوية (DS-TB) في المرضى الذين تبلغ أعمارهم 12 عامًا أو أكثر ويزيد وزنهم عن 40 كغ

References

Patients aged 12 years or older with pulmonary DS-TB may receive a 4-month regimen of isoniazid, rifapentine, moxifloxacin and pyrazinamide (2HPMZ/2HPM).

Adults and children aged 12 years or older with a body weight of more than 40 kg and affected by pulmonary DS-TB are eligible for this regimen, including those who are also HIV-positive with a CD4 count of more than 100 cells/mm3 and patients with diabetes.

Patients aged 12 years or more with pulmonary DS-TB may receive the 4-month regimen 2HPMZ/2HPM, which comprises rifapentine, isoniazid, pyrazinamide and moxifloxacin (2 months of isoniazid, rifapentine, moxifloxacin and pyrazinamide, followed by 2 months of isoniazid, rifapentine and moxifloxacin).

The dose of rifapentine used was fixed at 1200 mg and moxifloxacin at 400 mg.

NTPs need to monitor patients' condition with regular clinical follow-ups and may perform at least smear microscopy after 2 months of treatment to monitor treatment response bacteriologically.